Table of Content

  1. INTRODUCTION
    1. Study Assumptions and Market Definition
    2. Scope of the Study
  2. RESEARCH METHODOLOGY
  3. EXECUTIVE SUMMARY
  4. MARKET DYNAMICS
    1. Market Overview
    2. Market Drivers
      1. Increased Prevalence of Fibrosis Diseases
    3. Market Restraints
      1. Limited Treatment Efficacy for Advanced Stages
      2. Challenges in Early Diagnosis
    4. Market Opportunities
      1. Introduction of Advanced Treatment Options
    5. Market Trends
      1. Advancements in Precision Medicine
  5. MARKET SEGMENTATION
    1. By Drug Type
      1. Nintedanib
      2. Pirfenidone
      3. Other Drug Types
    2. By Mode of Action
      1. Antifibrotic Agents
      2. Tyrosine Kinase Inhibitors
      3. Other Modes of Action
    3. By End User
      1. Hospitals and Clinics
      2. Pharmacies
      3. Other End Users
    4. By Key Geographic Regions
      1. North America
        1. United States
        2. Canada
        3. Mexico
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Rest of Europe
      3. Asia Pacific
        1. China
        2. Japan
        3. India
        4. Australia
        5. South Korea
        6. Rest of Asia Pacific
      4. Middle East and Africa
        1. GCC
        2. South Africa
        3. Rest of Middle East and Africa
      5. South America
        1. Brazil
        2. Argentina
        3. Rest of South America
  6. COMPETITIVE LANDSCAPE
    1. Company Profile
      1. Avalyn Pharma Inc.
      2. Boehringer Ingelheim International GmbH
      3. Bristol-Myers Squibb Company
      4. CS Pharmaceuticals United Therapeutics Corporation
      5. Cipla Inc.
      6. F. Hoffmann-La Roche Ltd
      7. FibroGen Inc.
      8. Horizon Therapeutics Inc.
      9. Jubliant Pharma Limited (JubliantCadista Limited)
      10. MediciNova Inc.
      11. Merck & Co. Inc.
      12. United Therapeutics Corporation
  7. MARKET OPPORTUNITIES AND FUTURE TRENDS


Frequently Asked Questions

Q.1. What is the projected market value of the global Idiopathic Pulmonary Fibrosismarket?

The global market of Idiopathic Pulmonary Fibrosis is projected to reach USD 7.4 Bn by 2033.

Q.2. What is the estimated growth rate (CAGR) of the global Idiopathic Pulmonary Fibrosismarket?

The global Idiopathic Pulmonary Fibrosis market has an estimated annual growth rate of 6.4% .

Q.3. What are the recent trends of Idiopathic Pulmonary Fibrosismarket?

Advancements in precision medicineis one of the major trends of the market that is projected to boost the market growth in the near future.

 

Q.4. Which are the top companies to hold the market share in Idiopathic Pulmonary Fibrosis?

The major companies profiled in this report include Avalyn Pharma Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, CS Pharmaceuticals  United Therapeutics Corporation, Cipla Inc., F. Hoffmann-La Roche Ltd, FibroGen Inc., Horizon Therapeutics Inc., Jubliant Pharma Limited (JubliantCadista Limited), MediciNova Inc., Merck & Co. Inc., United Therapeutics Corporation, among others.

Q.5. Which region is estimated to held highest CAGR inIdiopathic Pulmonary Fibrosismarket?

North America is estimated to hold biggest share in the market for Idiopathic Pulmonary Fibrosis.

 

Why Choose Us

Inclusion of Pre-clinical Molecules

Other than an extensive coverage of clinical and commercial drugs, our reports also provide details about pre-clinical molecules!

Start-up
Profiling

One of our marquee services We profile relevant start-up companies in the market.

KOL
Insight's

Get access to reliable data our insights and analyses are backed by Key Opinion Leaders in the field.

Specialized in Healthcare

Our team comprises of industry specialists and research experts from life sciences area holding degree in Medicine, Doctor of Pharmacy, M.Sc. in Pharmacy, Pharma MBAs, and Biotechnology.